{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:09:18Z","timestamp":1790222958454,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["PO1CA250972"],"award-info":[{"award-number":["PO1CA250972"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH1910285"],"award-info":[{"award-number":["W81XWH1910285"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ijrobp.2025.09.072","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T04:32:20Z","timestamp":1764390740000},"page":"566-575","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Enhanced Antitumor Efficacy of 225Ac-NM600 Compared to 177Lu-NM600 in Prostate Cancer Models"],"prefix":"10.1016","volume":"125","author":[{"given":"Carolina A.","family":"Ferreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemanth K.","family":"Potluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"Tantawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher F.","family":"Massey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Grudzinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda M.","family":"Carston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan B.","family":"Clemons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malick Bio","family":"Idrissou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna S.","family":"Thickens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary T.","family":"Rosenkrans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline P.","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anatoly N.","family":"Pinchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ohyun","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin J.","family":"Jeffery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan P.","family":"Bednarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary S.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamey P.","family":"Weichert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas G.","family":"McNeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinier","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.09.072_bib0001","unstructured":"Quaye E. Prostate cancer statistics for 2024. Cancer Therapy Advisor. 2024. Available at: https:\/\/www.cancertherapyadvisor.com\/factsheets\/prostate-cancer-statistics\/. Accessed January 14, 2026."},{"key":"10.1016\/j.ijrobp.2025.09.072_bib0002","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1053\/j.seminoncol.2018.10.001","article-title":"Current therapeutic options in metastatic castration-resistant prostate cancer","volume":"45","author":"Ingrosso","year":"2018","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.072_bib0003","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1200\/OP.21.00206","article-title":"Recent advances in the management of metastatic prostate cancer","volume":"18","author":"Sayegh","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.ijrobp.2025.09.072_bib0004","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","article-title":"FDA approval summary: Lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer","volume":"29","author":"Fallah","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.09.072_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1159557","article-title":"PARP inhibitors in metastatic prostate cancer","volume":"13","author":"Taylor","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.072_bib0006","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: Clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ijrobp.2025.09.072_bib0007","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.09.072_bib0008","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","article-title":"225Ac-PSMA-617 for PSMA-targeted \u03b1-radiation therapy of metastatic castration-resistant prostate cancer","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.09.072_bib0009","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00259-015-3174-7","article-title":"Dosimetry for (177)Lu-DKFZ-PSMA-617: A new radiopharmaceutical for the treatment of metastatic prostate cancer","volume":"43","author":"Delker","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2025.09.072_bib0010","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/cancers13040779","article-title":"Preclinical and clinical status of PSMA-targeted alpha therapy for metastatic castration-resistant prostate cancer","volume":"13","author":"Juzeniene","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ijrobp.2025.09.072_bib0011","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2967\/jnumed.116.187021","article-title":"\u03b1- Versus \u03b2-emitting radionuclides for pretargeted radioimmunotherapy of carcinoembryonic antigen\u2013expressing human colon cancer xenografts","volume":"58","author":"Heskamp","year":"2017","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ijrobp.2025.09.072_bib0012","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2967\/jnumed.120.251983","article-title":"Comparison of CD38-targeted \u03b1- versus \u03b2-radionuclide therapy of disseminated multiple myeloma in an animal model","volume":"62","author":"Minnix","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.09.072_bib0013","doi-asserted-by":"crossref","first-page":"240ra75","DOI":"10.1126\/scitranslmed.3007646","article-title":"Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy","volume":"6","author":"Weichert","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ijrobp.2025.09.072_bib0014","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.2967\/jnumed.118.224808","article-title":"Preclinical characterization of 86\/90Y-NM600 in a variety of murine and human cancer tumor models","volume":"60","author":"Grudzinski","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.09.072_bib0015","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2967\/jnumed.119.236265","article-title":"177Lu-NM600 targeted radionuclide therapy extends survival in syngeneic murine models of triple-negative breast cancer","volume":"61","author":"Hernandez","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.09.072_bib0016","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s42003-019-0327-4","article-title":"90Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell non-Hodgkin\u2019s lymphoma","volume":"2","author":"Hernandez","year":"2019","journal-title":"Commun Biol"},{"key":"10.1016\/j.ijrobp.2025.09.072_bib0017","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1021\/jm990141f","article-title":"Improved in vivo stability of actinium-225 macrocyclic complexes","volume":"42","author":"Deal","year":"1999","journal-title":"J Med Chem"},{"key":"10.1016\/j.ijrobp.2025.09.072_bib0018","first-page":"155","article-title":"Development and validation of RAPID: A patient-specific Monte Carlo three-dimensional internal dosimetry platform","volume":"33","author":"Besemer","year":"2018","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.ijrobp.2025.09.072_bib0019","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3389\/fonc.2012.00153","article-title":"Radiation as an immunological adjuvant: Current evidence on dose and fractionation","volume":"2","author":"Demaria","year":"2012","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.072_bib0020","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3389\/fonc.2012.00095","article-title":"Role of T lymphocytes in tumor response to radiotherapy","volume":"2","author":"Demaria","year":"2012","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.072_bib0021","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fimmu.2019.00193","article-title":"Role of radiation therapy in modulation of the tumor stroma and microenvironment","volume":"10","author":"Menon","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijrobp.2025.09.072_bib0022","first-page":"3276","article-title":"Effects of radiation on T regulatory cells in normal states and cancer: Mechanisms and clinical implications","volume":"5","author":"Liu","year":"2015","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.09.072_bib0023","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000826","article-title":"Combination of radiotherapy and suppression of Tregs enhances abscopal antitumor effect and inhibits metastasis in rectal cancer","volume":"8","author":"Ji","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ijrobp.2025.09.072_bib0024","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002038","article-title":"Radiation dose and fraction in immunotherapy: One-size regimen does not fit all settings, so how does one choose?","volume":"9","author":"Demaria","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ijrobp.2025.09.072_bib0025","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1158\/1078-0432.CCR-20-2293","article-title":"High-dose per fraction radiotherapy induces both antitumor immunity and immunosuppressive responses in prostate tumors","volume":"27","author":"Lin","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.09.072_bib0026","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41416-020-0956-x","article-title":"Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model","volume":"123","author":"Philippou","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2025.09.072_bib0027","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s13014-014-0275-6","article-title":"Hypofractionated radiotherapy for prostate cancer","volume":"9","author":"Hegemann","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.072_bib0028","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13014-018-1040-z","article-title":"The alfa and beta of tumours: A review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies","volume":"13","author":"van Leeuwen","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.072_bib0029","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2967\/jnumed.108.058651","article-title":"MIRD Pamphlet No. 22 (abridged): Radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy","volume":"51","author":"Sgouros","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.09.072_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/14736691211060117","article-title":"ICRU Report 96: dosimetry-guided radiopharmaceutical therapy","volume":"21","author":"Sgouros","year":"2022","journal-title":"J ICRU"},{"key":"10.1016\/j.ijrobp.2025.09.072_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1563387","article-title":"Immunomodulatory effects of alpha vs beta radiopharmaceutical therapy in murine prostate cancer","volume":"16","author":"Ferreira","year":"2025","journal-title":"Front Immunol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625063412?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625063412?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:19:33Z","timestamp":1780388373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625063412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0360301625063412"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.09.072","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced Antitumor Efficacy of 225Ac-NM600 Compared to 177Lu-NM600 in Prostate Cancer Models","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.09.072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}